Skip to main navigation
Telix Pharmaceuticals Limited Logo
  • Overview
  • News
  • Events & Presentations
    • Events
    • Presentations
  • Financials
    • Half-year & Quarterly Results
    • Annual Reports & AGMs
    • ASX Announcements
    • SEC Filings
  • Pipeline
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Board & Management
    • Documents & Charters
    • Sustainability
  • Resources
    • Shareholder Information
    • Investor Resources
    • Email Alerts
    • Contact Us

Release Details

Telix Completes Enrollment in Phase 3 BiPASS Study

02 Sep 2026
36a7f721-2dd3-4050-84fc-ea141513d1e0.pdf

Subscribe to our Email Alerts

©2026 Telix Pharmaceuticals Limited.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. This website is intended for corporate communication and investor relations purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Forward Looking Statements
  • Twitter
  • LinkedIn
  • Facebook
  • YouTube
Search Investors